Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Journal of Medical Economics
|
June 3, 2018
Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands
Alexandre Gherardi, Stéphane Roze, Johan Kuijvenhoven, et al.
European Urology Open Science
|
March 6, 2023
Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
Hannah Collacott, Nicolas Krucien, Sebastian Heidenreich, et al.
Parkinsonism & Related Disorders
|
June 27, 2006
Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement
Jonas Hjelmgren, Ola Ghatnekar, Jan Reimer, et al.
The Journal of Sexual Medicine
|
August 14, 2013
Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden
Stefan Arver, Ba Luong, Anina Fraschke, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
May 11, 2012
Societal value of stem cell therapy in stroke--a modeling study
Johanna Svensson, Ola Ghatnekar, Arne Lindgren, et al.
Clinical Therapeutics
|
October 9, 2008
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis
Ola Ghatnekar, Thor Alvegård, Nils Conradi, et al.
International Journal of Cancer
|
May 8, 2013
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature
Ola Ghatnekar, Roland Andersson, Marianne Svensson, et al.
Pharmacoeconomics - Open
|
February 3, 2023
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Owen Alan Edwards Cooper, Ola Ghatnekar, Natalia Piglowska, et al.
Drug Safety
|
May 22, 2010
Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation
Alejandro Arana, Sam Allen, Jörg Burkowitz, et al.
Annals of Gastroenterology
|
September 4, 2020
The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink
Ailsa Hart, Siew C Ng, John Watkins, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Journal of Medical Economics
|
June 3, 2018
Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands
Alexandre Gherardi, Stéphane Roze, Johan Kuijvenhoven, et al.
European Urology Open Science
|
March 6, 2023
Patient Preferences for Treatment of Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment
Hannah Collacott, Nicolas Krucien, Sebastian Heidenreich, et al.
Parkinsonism & Related Disorders
|
June 27, 2006
Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement
Jonas Hjelmgren, Ola Ghatnekar, Jan Reimer, et al.
The Journal of Sexual Medicine
|
August 14, 2013
Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden
Stefan Arver, Ba Luong, Anina Fraschke, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
May 11, 2012
Societal value of stem cell therapy in stroke--a modeling study
Johanna Svensson, Ola Ghatnekar, Arne Lindgren, et al.
Clinical Therapeutics
|
October 9, 2008
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis
Ola Ghatnekar, Thor Alvegård, Nils Conradi, et al.
International Journal of Cancer
|
May 8, 2013
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature
Ola Ghatnekar, Roland Andersson, Marianne Svensson, et al.
Pharmacoeconomics - Open
|
February 3, 2023
Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
Owen Alan Edwards Cooper, Ola Ghatnekar, Natalia Piglowska, et al.
Drug Safety
|
May 22, 2010
Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation
Alejandro Arana, Sam Allen, Jörg Burkowitz, et al.
Annals of Gastroenterology
|
September 4, 2020
The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink
Ailsa Hart, Siew C Ng, John Watkins, et al.
Page
of 2